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2 Here we day +350. A total of 1.3 × 10 10 mononuclear cells, equivalent describe the potency of a graft-versus-myeloma effect in a to 1.45 × 10 8 /kg recipient bw were transfused, with 43% CD3 + patient, who relapsed after sibling BMT with extramedullary T cells (6.2 × 10 7 /kg) respectively. To enhance the allogeneic cutaneous plasmacytomas.
T cell effect, alpha interferon was added with six consecutive doses each 5 million units s.c., starting day +360. On day +365 the tumors started to shrink, and they had completely Case vanished by day +400 (Figure 3 ). Serum analysis demonstrated
This 53-year-old man presented with multiple myeloma IgG kappa in July 1993. The initial stage of disease was II A according to Salmon and Durie without renal dysfunction, no osteolytic lesions or extramedullary tumor manifestations. Bone marrow biopsy revealed a 70% infiltration and the peripheral blood smear showed 10% plasma cells. The initial chemotherapy with vincristine, doxorubicin and dexamethasone resulted in a good partial remission. In January 1994 disease progression occurred to plasma cell leukemia (77% plasma cells in the peripheral blood), and in March 1994 an autologous peripheral blood stem cell transplantation was performed after conditioning with a total dose of 900 mg Ara-C and melphalan 200 mg/m 2 with good partial response. In the 
Figure 4
Serum electrophoresis: time course of monoclonal paraprotein. 28.9.93: after first VAD chemotherapy M-gradient remains detectable; 1.2.94: leukemic relapse; 28.6.94: relapse after autologous peripheral blood stem cell transplantation; 15.9.95: after allogeneic BMT; 2.8.95: extramedullary relapse with solid tumor manifestation; 6.10.95: after successful adoptive immunotherapy.
Figure 3
Patient's right forearm on day +400.
Discussion
Our case presents a striking example for the power of a graftversus-myeloma effect (GVM), which has not been apprecicomplete disappearance of the paraprotein, however, the patient developed diarrhea, reflecting a histologically conated until recently. Buffy coat transfusions for adoptive immunotherapy are often associated with a considerable morbidity firmed acute intestinal GVHD. Grade III GVHD of the liver and gut were treated by restarting immunosuppression with due to acute GVHD, which has been proposed to be related to the T cell dose. 4 A possible role of transfused donor T cells CsA and steroids. Because of slow improvement, our patient received murine anti-CD25 interleukin-2 receptor monoin relapsing multiple myeloma after allogeneic sibling and matched unrelated BMT has been shown recently in two insticlonal antibodies (Leucotac; Biotest, Dreieich, Germany) 10 mg/day for 10 days, followed by 5 mg/day for 10 days. 3 tutes, 5, 6 and transfer of myeloma idiotype-specific T cell response was successfully demonstrated in an actively immuGut GVHD resolved, and chronic GVHD of the liver is improving, allowing the tapering of CsA and steroids. The nized marrow donor. 7 In our report we could show that the GVM effect is highly patient is in continuous complete remission as shown by negative immunofixation 259 days post-buffy coat transfusion efficient even in the matched related situation. It is likely that this effect is due to the buffy coat infusions, but we cannot (Figure 4 ). This result was confirmed by fluorescence in situ hybridization (FISH). Out of 200 interphases examined 197 completely rule out, that this GVM effect is caused by discontinuation of the immunosuppressive therapy. Also, it may be (97%) showed a female karyotype. In January 1996 the patient again had a worsening of his chronic GVHD of the liver and an additive effect, because compared to other authors, who treated patients with bone marrow relapse of MM, we had a skin and immunosuppression had to be increased again. Tapering of CsA and MP was possible recently, however, the very rapid response. In the report of Verdonck et al 5 the two patients with MM relapse after T cell-depleted BMT responded patient is still on ambulatory treatment for his extensive chronic GVHD. There is no evidence of relapse of the tumors to adoptive immunotherapy after 2-4 months and with Tricot 6 it took 28 days. In patients with other malignancies (CML or and immunofixation is still negative 259 days post-buffy coat transfusion and 609 days post-BMT.
acute leukemia), response to allogeneic T cells was seen in matched unrelated allogeneic transplantation.
5 Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ. Graft-versus-myeloma effect in two cases. Lancet 1996; 347; 800-801. 6 Tricot G, Vesole D, Jagannath S, Munshi N, Barlogie B. Graft-
